MedPath

Perrigo

🇮🇪Ireland
Ownership
Private
Employees
9.1K
Market Cap
$3.9B
Website
Introduction

Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Clinical Trials

4

Active:0
Completed:1

Trial Phases

1 Phases

Not Applicable:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Not Applicable
4 (100.0%)

Comparative Study for the Evaluation of Two Medical Devices on the Treatment of Head Lice Infestation

Not Applicable
Recruiting
Conditions
Head Lice Infestation
First Posted Date
2023-09-28
Last Posted Date
2023-09-28
Lead Sponsor
Perrigo CSCI
Target Recruit Count
136
Registration Number
NCT06057506
Locations
🇲🇺

Insight Research, Quatre Bornes, Mauritius

Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation

Not Applicable
Conditions
Head Lice
First Posted Date
2022-05-18
Last Posted Date
2022-06-01
Lead Sponsor
Perrigo CSCI
Target Recruit Count
136
Registration Number
NCT05379114
Locations
🇲🇺

Céline Lhéritier, Quatre Bornes, Mauritius

Effects of Arterin Cholesterol for Reduction of Lipid Levels

Not Applicable
Conditions
Blood Cholesterol Lowers
LDL-C
First Posted Date
2021-02-11
Last Posted Date
2021-02-11
Lead Sponsor
Perrigo CSCI
Target Recruit Count
114
Registration Number
NCT04749784
Locations
🇩🇪

analyze & realize GmbH, Berlin, Germany

DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects

Not Applicable
Completed
Conditions
Overweight
Obesity
First Posted Date
2019-09-12
Last Posted Date
2023-11-28
Lead Sponsor
Perrigo CSCI
Target Recruit Count
178
Registration Number
NCT04086797
Locations
🇩🇪

analyze & realize GmbH, Berlin, Germany

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.